VMTHF Stock - Venus Medtech (Hangzhou) Inc.
Unlock GoAI Insights for VMTHF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $470.83M | $491.37M | $406.46M | $415.86M | $276.05M |
| Gross Profit | $367.75M | $389.20M | $314.00M | $324.34M | $227.28M |
| Gross Margin | 78.1% | 79.2% | 77.3% | 78.0% | 82.3% |
| Operating Income | $-346,597,000 | $-589,973,000 | $-650,214,000 | $-278,644,000 | $-178,607,000 |
| Net Income | $-714,307,000 | $-703,754,000 | $-1,057,699,000 | $-373,636,000 | $-181,989,000 |
| Net Margin | -151.7% | -143.2% | -260.2% | -89.8% | -65.9% |
| EPS | $-1.63 | $-1.61 | $-2.42 | $-0.85 | $-0.44 |
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
VMTHFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | — | — | — | — |
Q3 2025 | Sep 1, 2025 | $-0.05 | $-0.04 | +12.1% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-0.08 | — | — | — |
Q3 2024 | Aug 30, 2024 | $-0.06 | $-0.47 | -736.1% | ✗ MISS |
Q2 2024 | Jun 28, 2024 | $-0.08 | $-0.81 | -871.6% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-0.09 | $-0.80 | -765.8% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-0.05 | $-1.95 | -4115.6% | ✗ MISS |
Q3 2022 | Aug 31, 2022 | $-0.02 | $-0.07 | -253.9% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | $-0.03 | $-0.43 | -1492.4% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | $-0.02 | $-0.43 | -2017.1% | ✗ MISS |
Q4 2020 | Dec 31, 2020 | $-0.00 | $-0.22 | -7166.0% | ✗ MISS |
Q2 2020 | Jun 30, 2020 | — | $-0.22 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.61 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.61 | — | — |
Latest News
Frequently Asked Questions about VMTHF
What is VMTHF's current stock price?
What is the analyst price target for VMTHF?
What sector is Venus Medtech (Hangzhou) Inc. in?
What is VMTHF's market cap?
Does VMTHF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VMTHF for comparison